News
Eli Lilly sues four telehealth compounding GLP-1 companies
Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth companies were misleading consumers and illegally prescribing compounded versions of its glucagon-like peptide-1 agonist drugs Mounjaro and Zepbound.
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...
Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...
Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to expect from LLY's Q1 results.
Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...
Barchart on MSN2d
Eli Lilly's Quarterly Earnings Preview: What You Need to KnowWith a market cap of $775.6 billion, Eli Lilly and Company (LLY) is a global biopharmaceutical leader with leading products ...
Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock ...
Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback